estimated people die every year from HIV
Most people know of the U.S. HIV epidemic of 1980s, and although the alarming death rates due to HIV/AIDS has slowed, it is still a prominent and fatal disease. HIV is still one of the top causes of death worldwide.
estimated people are infected with HIV each year
infections occur everyday through maternal-to-child transmission
children die everyday from HIV infection
Current Treatment for HIV is Toxic and Expensive
Antiretroviral chemothereapy (ARV) is currently used to suppress HIV symptoms—but require lifelong treatment and can have major consequences.
In the U.S., the FDA has approved the use of ARVs (antiretroviral chemotherapy) as the main treatment for HIV patients. And though ARVs can improve a patient's health for decades, they are highly toxic. ARVs can cause severe damage to organs including the heart and kidneys, decrease bone-mineral density, and result in Vitamin D deficiency. ARVs treatment is also necessary for life and average cost of treatment is $14,000-$20,000 a year.
of people living with HIV are receiving treatment
estimated cost of lifetime treatment with ARVs
On Our Way to a Cure for HIV
We've created an antibody that targets & neutralizes infectious diseases like HIV.
At BioClonetics Immunotherapeutics, we’re one step closer to ending the search for the HIV cure. We have discovered and developed a proprietary cell line that produces a fully-human antibody proven to specifically target and effectively neutralize HIV-1.
Already Verified in Five Different Laboratories
Take a Closer Look at the Treatment
Clone 3 is what’s known as a monoclonal antibody—a laboratory-made molecule produced by repeated replication of a single parent cell.
Monoclonal antibodies mimic the ones your body naturally produces as part of your immune system's response to germs, viruses and other invaders. Because monoclonal antibodies come from a single cell source, they’re engineered to target a specific part of a virus. The Clone 3 monoclonal antibodies that we’re developing target a specific site on HIV.
What We've Achieved So Far
BioClonetics has laid the groundwork for a major breakthrough in the fight against HIV, and we’ve gained some incredible traction in our efforts.
The Completed Research
Isolating and cloning of the B cells of HIV patients to create monoclonal antibodies. Screening of the resulting antibodies and the identification of Clone 3. In-vitro testing of Clone 3 against HIV strains to confirm neutralizing capability. Identification of the binding site of Clone 3 on the HIV virus. Identification of the complete heavy chain and light chain amino acid structure of Clone 3.
Potential Strategic Partnerships
A major pharmaceutical company has indicated that it will further consider our technology once we have successfully completed the next step of producing and testing what is known as the “recombinant” form of Clone 3.
Manufacturing and Distribution
We have several world-class laboratories with whom we are working who will assist us in conducting the next steps of our plan.
Our Next Steps
Producing the recombinant of the Clone 3 antibody for testing and later patient therapy
Testing of the recombinant against HIV strains to validate effectiveness
Pre-clinical primate macaque trials to validate effectiveness in primates
Help Us Defeat HIV
To all potential investors,
We hope you have had an opportunity to review our technology and its potential for providing a meaningful and revolutionary therapy for HIV patients. We have laid out information showing the potential of our technology - and even more information may be found on our website.
All of that information is about the therapeutic potential of our technology. However, let me share information about another side of our effort – namely the underlying motivation.
As Pollyannaish as it may sound, the primary motivation of each member of our team is the desire to save lives. Each year, HIV takes the lives of over 1.2 million individuals. And in 2015, 190,000 children died of AIDS-related illnesses (over 500 each day).
Approximately 2 million people are newly infected each year with HIV. And over 36 million individuals today have the virus.
The time for a cure for HIV has long since passed. However, the efforts of Big Pharm have been misdirected, either through its failure to properly apply new and more effective technology or a desire to focus on the financial bottom line rather than the needs of patients – perhaps with a focus on profit from providing a treatment and not a cure.
With regard to HIV, all one needs to know is that 400 to 500 children die each day from this disease. This is almost twice the number who perish from cancer. However, this present day tragedy is allowed to continue day to day, week to week and year to year without proper focus or financial support from either governments or the private or big Pharma establishments.
We recognize however that sometimes good intentions are not enough to raise capital needed to properly address a pandemic that has existed for decades. Indeed, you are probably reading this letter with the rightful focus on the potential for a probable successful financial investment. While we have as a primary focus the good that can come from our technology, it is a fact, and in this day sometimes a rare situation, that our case presents both a potential for humanitarian good and financial reward.
We believe that our technology provides the rare opportunity to invest in something that is meaningful for mankind and particularly in areas of the world where medical therapies are not as readily available as in the US, and at the same time provide the potential for financial success. As to this potential, we point to the fact that $16 Billion is now spent every year on antiretroviral drugs that treat but do not cure HIV patients. As an investor, I am sure your interest is focused initially on the financial potential, but in this case, you can participate both in that potential as well as the potential humanitarian benefit that arises for a cure for HIV. Your contribution would be a step toward both.
We hope you will join us in this endeavor.
Charles S. Cotropia
BioClonetics Immunotherapeutics, Inc.